Study S000354

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00974272
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 39
Start: 2006-08
Primary completion: 2008-11
Lead sponsor: Carl T. Hayden VA Medical Center
Conditions: Type 2 Diabetes Mellitus; Impaired Glucose Tolerance
Interventions: DRUG:Exenatide; OTHER:Normal Saline
Results posted: FALSE

Registered primary outcomes

Triglyceride concentration in serum [Before and up to 8-hours post-injection]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027049	Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Schwartz EA, Atherosclerosis	2010	Randomized trial	PMID 20557887 DOI	cites ClinicalTrials.gov:NCT00974272; registry reference DERIVED:20557887
R0027176	Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Koska J, Diabetes care	2010	Randomized trial	PMID 20200309 DOI	cites ClinicalTrials.gov:NCT00974272; registry reference DERIVED:20200309